Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)
Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Alessandra Di Lelio(Mario Negri Sud Foundation), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Mark Heaney(Immunovaccine (Canada)), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Lorenzo Marfisi(Mario Negri Institute for Pharmacological Research), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Marina Kremyanskaya(Tisch Cancer Institute), John Mascarenhas(Tisch Hospital), Amylou C. Dueck(Mayo Clinic in Arizona), Elizabeth O. Hexner(University of Pennsylvania), Gianni Tognoni(Fondazione Lelio e Lisli Basso), Camille N. Abboud(Washington University in St. Louis), Eliseo Serone(University of L'Aquila), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Giuseppe Prosperini(Mario Negri Sud Foundation)
Cited by 14
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k